• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Significance of measurable residual disease in adults with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.接受异基因造血细胞移植的继发性急性髓系白血病成年患者中可测量残留病的意义。
Bone Marrow Transplant. 2022 Nov;57(11):1732-1734. doi: 10.1038/s41409-022-01794-4. Epub 2022 Aug 27.
2
Measurable residual disease for secondary acute myeloid leukemia prior to allogeneic hematopoietic cell transplantation: does it make a difference?异基因造血细胞移植前继发性急性髓系白血病的可测量残留病：有影响吗？
Bone Marrow Transplant. 2022 Oct;57(10):1473-1474. doi: 10.1038/s41409-022-01765-9. Epub 2022 Jul 28.
3
Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.可测量残留病状态对接受异基因造血细胞移植的急性髓系白血病成人患者复发和生存预测准确性的贡献。
Haematologica. 2023 Jan 1;108(1):273-277. doi: 10.3324/haematol.2022.281631.
4
Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid Malignancy.髓系恶性肿瘤患者在减低强度异基因移植前的可测量残留病
J Clin Oncol. 2021 Jul 20;39(21):2413-2415. doi: 10.1200/JCO.21.00255. Epub 2021 May 5.
5
Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.可测量残留疾病、调理方案强度和年龄可预测首次缓解的急性髓系白血病患者接受异基因造血细胞移植的结果：欧洲血液和骨髓移植学会急性白血病工作组对 2292 例患者的注册分析。
Am J Hematol. 2018 Sep;93(9):1142-1152. doi: 10.1002/ajh.25211. Epub 2018 Aug 15.
6
WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.WT1 可测量残留病检测在接受异基因造血干细胞移植的急性髓系白血病患者中的应用：最佳时间点、阈值和候选者。
Biol Blood Marrow Transplant. 2019 Oct;25(10):1925-1932. doi: 10.1016/j.bbmt.2019.05.033. Epub 2019 Jun 4.
7
Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后可测量的残余克隆性造血对急性髓系白血病患者预后的影响。
Leukemia. 2024 Jan;38(1):198-201. doi: 10.1038/s41375-023-02072-y. Epub 2023 Oct 25.
8
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival.在中危急性髓系白血病患者中，可测量残留病指导的治疗是一种有价值的策略，可减少异基因移植，且不会对生存产生负面影响。
Haematologica. 2023 Oct 1;108(10):2794-2798. doi: 10.3324/haematol.2022.282639.
9
Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study.干扰素-α 对异基因造血干细胞移植后 t(8;21) 急性髓系白血病患者微小残留病的治疗有效：一项前瞻性登记研究的结果。
Oncologist. 2018 Nov;23(11):1349-1357. doi: 10.1634/theoncologist.2017-0692. Epub 2018 Aug 3.
10
Measurable residual disease evaluated by flow cytometry using leukemia associated immune phenotypes following allogeneic stem cell transplantation is associated with high relapse rates in patients with acute myeloid leukemia.在异基因干细胞移植后，通过流式细胞术利用白血病相关免疫表型评估的可测量残留病与急性髓系白血病患者的高复发率相关。
Leuk Lymphoma. 2020 Mar;61(3):745-748. doi: 10.1080/10428194.2019.1686500. Epub 2019 Nov 11.

引用本文的文献

1
A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.CPX-351用于老年继发性或高危急性髓系白血病患者的2期多中心临床试验：PETHEMA-LAMVYX。
Cancer. 2025 Jan 1;131(1):e35618. doi: 10.1002/cncr.35618. Epub 2024 Oct 30.
2
Measurable residual disease as predictor of post-day +100 relapses after allografting in adult AML.可测量残留病作为成人急性髓系白血病同种异体移植后+100天复发的预测指标。
Blood Adv. 2025 Feb 11;9(3):558-570. doi: 10.1182/bloodadvances.2024013214.
3
Relationship between morphologic remission with or without hematologic recovery and outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia.成人急性髓系白血病异基因造血细胞移植后形态学缓解伴或不伴血液学恢复与预后的关系
Bone Marrow Transplant. 2024 Dec;59(12):1667-1675. doi: 10.1038/s41409-024-02407-y. Epub 2024 Aug 29.
4
[Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in the treatment of secondary acute myeloid leukemia].异基因造血干细胞移植治疗继发性急性髓系白血病的疗效及预后因素
Zhonghua Xue Ye Xue Za Zhi. 2024 Jan 14;45(1):41-47. doi: 10.3760/cma.j.cn121090-20230929-00151.
5
Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia.成人急性髓系白血病患者接受异基因造血细胞移植前的细胞毒性治疗、既往血液系统疾病与移植后结局之间的关联
Cancers (Basel). 2023 Jan 5;15(2):352. doi: 10.3390/cancers15020352.
6
Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remission.比较成人急性髓细胞白血病在首次或第二次缓解期接受异基因造血细胞移植时采用的减低强度和非清髓性预处理方案。
Bone Marrow Transplant. 2023 Apr;58(4):377-385. doi: 10.1038/s41409-022-01909-x. Epub 2022 Dec 28.
7
The present and future of measurable residual disease testing in acute myeloid leukemia.可测量残留病检测在急性髓细胞白血病中的现状与未来。
Haematologica. 2022 Dec 1;107(12):2810-2822. doi: 10.3324/haematol.2022.282034.

本文引用的文献

1
Unified classification and risk-stratification in Acute Myeloid Leukemia.急性髓系白血病的统一分类和危险分层。
Nat Commun. 2022 Aug 8;13(1):4622. doi: 10.1038/s41467-022-32103-8.
2
Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia.成人急性髓系白血病异基因造血细胞移植后残留细胞遗传学异常和流式细胞术可测量残留病对结局的相对影响。
Haematologica. 2023 Feb 1;108(2):420-432. doi: 10.3324/haematol.2022.281585.
3
Measurable residual disease for secondary acute myeloid leukemia prior to allogeneic hematopoietic cell transplantation: does it make a difference?异基因造血细胞移植前继发性急性髓系白血病的可测量残留病：有影响吗？
Bone Marrow Transplant. 2022 Oct;57(10):1473-1474. doi: 10.1038/s41409-022-01765-9. Epub 2022 Jul 28.
4
Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT).异基因造血细胞移植前可测量残留病（MRD）状态对继发性急性髓系白血病结局的影响。来自欧洲血液和骨髓移植学会（EBMT）急性白血病工作组（ALWP）的研究。
Bone Marrow Transplant. 2022 Oct;57(10):1556-1563. doi: 10.1038/s41409-022-01748-w. Epub 2022 Jul 14.
5
Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML.成人 AML 中的移植前流式细胞术微小残留病动力学与预处理强度
Blood. 2022 Mar 17;139(11):1694-1706. doi: 10.1182/blood.2021014804.
6
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.2021 年急性髓系白血病微小残留病更新：来自欧洲白血病网微小残留病工作组的共识文件。
Blood. 2021 Dec 30;138(26):2753-2767. doi: 10.1182/blood.2021013626.
7
Measurable residual disease testing in acute myeloid leukaemia.急性髓系白血病的可测量残留病检测。
Leukemia. 2017 Jul;31(7):1482-1490. doi: 10.1038/leu.2017.113. Epub 2017 Apr 7.
8
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis.急性髓系白血病异基因造血细胞移植前的微小残留病：一项荟萃分析
Haematologica. 2017 May;102(5):865-873. doi: 10.3324/haematol.2016.159343. Epub 2017 Jan 25.
9
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理：2017年国际专家小组的欧洲白血病网络（ELN）建议
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
10
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.急性髓系白血病的发生是由独特的体细胞突变所定义的。
Blood. 2015 Feb 26;125(9):1367-76. doi: 10.1182/blood-2014-11-610543. Epub 2014 Dec 30.

Significance of measurable residual disease in adults with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.

作者信息

Rodríguez-Arbolí Eduardo, Orvain Corentin, Othus Megan, Walter Roland B

机构信息

Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.

Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), University of Seville, Seville, Spain.

出版信息

Bone Marrow Transplant. 2022 Nov;57(11):1732-1734. doi: 10.1038/s41409-022-01794-4. Epub 2022 Aug 27.

DOI:10.1038/s41409-022-01794-4
PMID:36030308
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10598788/
Abstract
摘要